This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Add These 5 Stocks With Solid Sales Growth to Your Portfolio
by Swayta Shah
While evaluating business growth, revenues are often more monitored than earnings. Let's check CarMax (KMX), Carlisle Companies (CSL), Qorvo (QRVO), First American Financial (FAF) & Cheniere Energy (LNG) as these are likely to witness strong top-line growth.
Here's Why it is Worth Investing in Carlisle (CSL) Stock Now
by Zacks Equity Research
Carlisle (CSL) is poised to benefit from strength across end markets, acquired assets and shareholder-friendly policies.
The Zacks Analyst Blog Highlights: Crane Co, Danaher, Carlisle Companies and LSB Industries
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Crane Co, Danaher, Carlisle Companies and LSB Industries
These 4 Diversified Players Look Interesting Now
by Sejuti Banerjea
This is a good time to be investing in conglomerates.
Carlisle's (CSL) Board Approves 3% Hike in Quarterly Dividend
by Zacks Equity Research
Carlisle (CSL) rewards shareholders with a 3% hike in the quarterly dividend rate. This underpins its strong cash position.
Carlisle (CSL) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Carlisle (CSL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Carlisle (CSL) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Carlisle (CSL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
IDEX (IEX) Q2 Earnings and Revenues Lag Estimates, Up Y/Y
by Zacks Equity Research
IDEX's (IEX) second-quarter 2021 revenues increase 22.2% year over year on account of impressive performance across its segments.
3M (MMM) Q2 Earnings and Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
3M's (MMM) second-quarter 2021 revenues increase 24.7% year over year on account of impressive performance across its segments.
Crane (CR) Q2 Earnings and Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
Crane's (CR) second-quarter 2021 revenues increase 23.6% year over year on account of impressive performance across Process Flow Technologies and Payment & Merchandising Technologies segments.
Carlisle (CSL) Q2 Earnings and Revenues Top Estimates, Up Y/Y
by Zacks Equity Research
Carlisle's (CSL) second-quarter 2021 revenues increase 22% year over year on impressive performance across CCM and CFT segments.
Carlisle (CSL) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Carlisle (CSL) delivered earnings and revenue surprises of 3.35% and 1.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Carlisle (CSL) to Buy Henry, To Boost Construction Business
by Zacks Equity Research
Carlisle's (CSL) Henry buyout is likely to strengthen its growth prospects in North America residential and commercial construction markets. Henry will be added to the Carlisle Construction Materials segment.
Carlisle (CSL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Carlisle (CSL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HC2 Holdings (HCHC) Completes Insurance Segment Divestment
by Zacks Equity Research
The divestment of the Insurance segment fetches HC2 Holdings (HCHC) $65 million in cash, which is part of the total consideration. It will help the company focus on other key businesses.
5 Stocks to Ride High in Booming Diversified Operations Industry
by Payal Jalan
Healthy pandemic-led demand and improving manufacturing activities are benefitting players in the Zacks Diversified Operations industry. DHR, CSL, ITT, CR and GFF are stocks with earnings potential.
Danaher's (DHR) Aldevron Buyout to Aid Genomic Medicine
by Zacks Equity Research
Danaher (DHR) to gain from the Aldevron acquisition as it will increase growth opportunities in the genomic medicine field. The acquired assets will be integrated with Danaher's Life Sciences segment.
Here's Why it is Worth Investing in Griffon (GFF) Stock Now
by Zacks Equity Research
Griffon (GFF) is likely to benefit from favorable macro trends, solid product offerings, well diversified business structure, sound manufacturing capacity, buyouts & shareholder-friendly policies.
MARUY vs. CSL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MARUY vs. CSL: Which Stock Is the Better Value Option?
General Electric (GE) Prices Tender Offer, To Reduce Debt
by Zacks Equity Research
General Electric's (GE) tender offer to buy notes issued by itself or GE Capital will help it lower leverage and strengthen the balance sheet. It progresses with the tender offer by pricing the notes.
New Strong Buy Stocks for June 9th
by Zacks Equity Research
CSL, MAT, SBSW, USAK, and ECHO have been added to the Zacks Rank #1 (Strong Buy) List on June 9, 2021.
Carlisle (CSL) Exhibits Strong Prospects, Risks Persist
by Zacks Equity Research
Carlisle (CSL) is poised to benefit from its exposure in diverse end markets, acquired assets and shareholder-friendly policies. However, soft end market and high debt level remain concerns.
Carlisle (CSL) Agrees to Divest CBF Segment to CentroMotion
by Zacks Equity Research
Carlisle's (CSL) sale of the CBF segment will help it simplify its portfolio and strengthen shareholder value. The divestment completion is expected in third-quarter 2021.
Carlisle (CSL) Moves 7.2% Higher: Will This Strength Last?
by Zacks Equity Research
Carlisle (CSL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Carlisle's (CSL) Q1 Earnings Top Estimates, Revenues Flat Y/Y
by Zacks Equity Research
Carlisle's (CSL) first-quarter 2021 revenues remain flat year over year on the back of weak performance across CIT segment. However, CCM, CFT and CBF units performed well.